RecruitingPhase IIEN original

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494Original on ClinicalTrials.gov ↗

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) damage response genes who have or have not already been treated with another PARP inhibitor. Talazoparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. All patients who take part on this study must have a gene aberration that changes how their tumors are able to repair DNA. This trial may help scientists learn whether some patients might benefit from taking different PARP inhibitors "one after the other" and learn how talazoparib works in treating patients with advanced cancer who have aberration in DNA repair genes.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

•Dorosły pacjent z potwierdzoną zmianą genetyczną w genach odpowiedzialnych za naprawę DNA, których nowotwór progresywnie się rozwijał mimo poprzedniego leczenia
•Posiadanie mutacji w genach BRCA1 lub BRCA2
•Posiadanie mutacji w genach zespołu Fanconiego (FANCA, FANCB, FANCC, FANCD2 i inne)
•Posiadanie mutacji w wybranych genach naprawy DNA (ATM, ATR, BRIP1, BAP1, CDK12, CHK2, RAD51 i inne)
•Wiek co najmniej 18 lat
•Dobry stan ogólny pacjenta (ECOG ≤ 2)
•Spodziewana długość życia dłuższa niż 3 miesiące
•Wykluwalne lub mierzalne ognisko nowotworu dostępne do pobrania próbki